缺血修饰蛋白与急性脑梗死体积的临床研究被引量：1

导出

摘要目的探讨急性脑梗死患者缺血修饰蛋白(IMA)水平与脑梗死体积的关系。方法选择发病24h急性脑梗死患者116例,按照脑梗死体积分为4组,分别为0~5 cm^3组(35例);5~10 cm^3组(32例);10~15 cm^3组(28例);(15 cm^3组(21例);选取同期来本院体检的20例健康者为对照组。运用ACB比色法来测定血清IMA水平。结果 0~5 cm^3组、5~10 cm^3组、10~15 cm^3组、(15 cm^3组缺血修饰蛋白水平存在显著差异(P<0.01),急性脑梗死组血清IMA水平(除(15 cm^3组)与脑梗死体积呈线性正相关(<0.01)。结论急性性脑梗死患者血清IMA水平均高于对照组,IMA可以作为脑组织缺血敏感的非特异性生化指标,并且急性脑梗死患者血清IMA水平随脑梗死体积增加而增高。可能作为辅助手段预测病情进展。

作者苏宏图张春荣石小晶杨文军王帅李霜梅

机构地区河北省秦皇岛市海港医院神经内科

出处《卒中与神经疾病》 2016年第2期132-134,共3页 Stroke and Nervous Diseases

关键词缺血修饰蛋白脑梗死体积脑梗死相关性

分类号 R743 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献10

1肖倩.缺血修饰白蛋白的研究进展和临床应用[J].实用中西医结合临床,2005,5(5):85-87. 被引量：8
2Bar-Or D,Lau E,Winkler JV.A novel assay for cobalt-albumin in binding and its potential as a marker for myocardial ischemia apreliminary report[J].Emerg Med,2000,19(4):3112-3150.
3Collinson PO,Gaze DC.Biomarkers of cardiovascular damage and dysfunction-an overview[J].Heart Lung Circ,2007,16(Suppl 3):S71-S82.
4Bar-Or D,Curt is G,Rao N,et al.Characterization of the Co2+and Ni2+binding amino-acid residues of the N terminus of human albumin.An in sight into the mechanism of a new assay for myocardial is chemia Eur[J].Biochem,2001,268(1):42-47.
5Bhagavan NV,Lai EM,Rios PA,et al.Evaluation of human serum albumin Cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction[J].Clin Chem,2003,49(4):581-585.
6易凯,李龙平,张华,王新华,谭亮南.缺血修饰白蛋白研究进展[J].检验医学教育,2007,14(4):37-40. 被引量：4
7Chan B,Dodsworth N,Woodrow J,et al.Site-specific N-terminal auto-degradation of human serum albumin[J].Eur J Biochem,1995,227(1/2):524-528.
8Abboud H,LabreucheJ,MeseguerE,Lavallee PC,et al.Ischemia-modified albumin in acute stroke[J].Cerebrovasc Dis,2007,23(2/3):216-220.
9唐晓斌,刘庆国,王英侠,王建伟.急性脑血管病24小时内缺血修饰白蛋白变化观察[J].中国医药导报,2011,8(25):159-161. 被引量：3
10陈家强,龚道元,李炜煊,潘晓芬,吴志刚,杨宇,伏红霞,彭艳,王晓娟.IMA、IL-6与缺血性脑卒中脑梗死体积的相关研究[J].医学检验与临床,2010(4):43-45. 被引量：10

二级参考文献29

1贾克刚,韩雪晶,唐红霞,南芳,张淑菊.应用全自动生化分析仪测定缺血修饰白蛋白[J].检验医学,2007,22(3):320-323. 被引量：21
2Moonis M, Thrombolytic therapy for Acute ischemic infarction: issues and answers [J]. Neurol India,2002,50:50-56.
3Bar D, Lau E, Winkler JV. A novel assay for cobalt albumin binding and its potential as a marker for myocardial ischemia preliminary report [J]. J Emerg Med,2000,19(4):3112-31502.
4Paul O, Co LF, FACB, et al. Biomarkers of cardiovascular damage and dysfunction-a nn overview [J]. Heart Lung and Circulation,2007,16:71- 82.
5Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the as- sessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T [J]. Int J Cardiol,2004,97(2):297-301.
6Chan B, Dodswo RN, Woodrow J, et al. Site-specific N-term inal auto degradation of human serum album in [J]. Eur J Biochem,1995,227(1- 2):524-528.
7tim P. Role and importance of biochemical markers in clinical cardiology [J]. Eur Heart J,2004,25(14):1187-1196.
8Sinha MK, Gaze DC, Tippins JR, et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention [J]. Circulation,2003,107:2403.
9Sinha MK, Roy D, Gaze DC, et al. Role of "ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes [J]. Emerg Med J,2004,21(1):29- 34.
10Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patient swith and without diabetes: a systematic overview [J]. Lancet,2000,355:773.